Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
|
| In millions, except per share items | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Clinical Development Services | 1,042.0 | 1,034.9 | 1,152.0 | | | | | |
| Laboratory Services | 313.1 | 274.6 | 263.9 | | | | | |
| Reimbursed revenue | 107.5 | 101.0 | 117.1 | | | | | |
| Belgium | 59.0 | 70.0 | 88.5 | 67.4 | | | | |
| Other | | | | 1,327.5 | | | | |
| Total revenues [+] | 1,470.6 | 1,416.8 | 1,551.4 | 1,394.9 | 1,247.7 | 1,037.1 | 841.3 | 727.0 |
| Services | 1,363.1 | 1,315.8 | 1,434.3 | | | | | |
| Revenue growth [+] | 3.8% | -8.7% | 11.2% | 11.8% | 20.3% | 23.3% | 15.7% | 19.4% |
| Clinical Development Services | 0.7% | -10.2% | | | | | | |
| Laboratory Services | 14.0% | 4.1% | | | | | | |
| Reimbursed revenue | 6.4% | -13.8% | | | | | | |
| Belgium | -15.8% | -20.9% | 31.3% | | | | | |
| Discovery Sciences | 26.9% | -65.7% | 4067.4% | -98.7% | -17.5% | 181.0% | -7.5% | |
| Cost of goods sold [+] | 763.3 | 731.8 | 807.2 | 761.5 | 670.5 | 550.5 | 452.8 | 382.2 |
| Reimbursable costs | | | | 119.1 | 101.4 | 75.1 | 67.3 | 57.5 |
| Gross profit | 707.3 | 685.0 | 744.2 | 633.4 | 577.2 | 486.6 | 388.5 | 344.8 |
| Gross margin | 48.1% | 48.4% | 48.0% | 45.4% | 46.3% | 46.9% | 46.2% | 47.4% |
| Selling, general and administrative | 81.9 | 81.1 | 68.4 | 332.6 | 304.0 | 251.4 | 203.2 | 166.3 |
| Research and development | 16.7 | 13.3 | 7.6 | 17.1 | 5.4 | 23.4 | 15.9 | 74.9 |
| Equity in earnings | -0.7 | -1.3 | | | | | | |
| Other operating expenses | 356.1 | 308.5 | 325.1 | 0.7 | | -5.1 | | -5.7 |
| EBITDA [+] | 252.9 | 282.0 | 344.4 | 284.7 | 267.7 | 216.9 | 169.4 | 109.4 |
| EBITDA growth | -10.3% | -18.1% | 21.0% | 6.3% | 23.4% | 28.0% | 54.9% | -17.5% |
| EBITDA margin | 17.2% | 19.9% | 22.2% | 20.4% | 21.5% | 20.9% | 20.1% | 15.0% |
| Depreciation | 66.2 | 65.1 | 60.4 | 55.6 | 47.7 | 40.3 | 28.6 | 27.0 |
| EBITA | 186.8 | 216.9 | 284.0 | 229.1 | 220.0 | 176.7 | 140.8 | 82.4 |
| EBITA margin | 12.7% | 15.3% | 18.3% | 16.4% | 17.6% | 17.0% | 16.7% | 11.3% |
| Amortization of intangibles | | | | | | | 1.2 | 1.6 |
| EBIT [+] | 186.8 | 216.9 | 284.0 | 229.1 | 220.0 | 176.7 | 139.6 | 80.8 |
| EBIT growth | -13.9% | -23.6% | 24.0% | 4.1% | 24.5% | 26.6% | 72.8% | -25.5% |
| EBIT margin | 12.7% | 15.3% | 18.3% | 16.4% | 17.6% | 17.0% | 16.6% | 11.1% |
| Non-recurring items [+] | | 3.9 | 1.6 | -0.7 | | | 2.8 | 1.9 |
| Asset impairment | -5.0 | -2.1 | 1.6 | -0.7 | | | 0.2 | |
| Interest income, net [+] | 2.9 | 4.5 | 16.1 | 18.0 | 14.6 | 7.7 | 2.0 | 1.5 |
| Interest expense | 1.0 | 0.7 | 0.5 | 0.3 | 0.5 | 1.1 | 0.5 | 0.8 |
| Interest income | 4.0 | 5.2 | 16.7 | 18.3 | 15.1 | 8.8 | 2.5 | 2.3 |
| Other income (expense), net [+] | -1.5 | -3.0 | -19.1 | 0.0 | 0.9 | -4.6 | -0.2 | -9.1 |
| Impairment of investments | -5.0 | -2.1 | -17.7 | | | | | |
| Other | | | | | | -1.3 | -1.8 | -1.0 |
| Pre-tax income | 188.2 | 214.5 | 279.4 | 247.7 | 235.5 | 179.8 | 138.6 | 71.2 |
| Income taxes | 60.8 | 62.9 | 91.5 | 84.4 | 78.9 | 59.9 | 46.9 | 24.9 |
| Tax rate | 32.3% | 29.3% | 32.7% | 34.1% | 33.5% | 33.3% | 33.8% | 35.0% |
| Minority interest | 0.4 | | | | | | | |
| Earnings from continuing ops | 127.3 | 151.6 | 187.9 | 163.3 | 156.7 | 119.9 | 91.7 | 46.3 |
| Earnings from discontinued ops | -3.7 | 7.7 | -0.4 | 0.1 | | | | |
| Net income | 123.7 | 159.3 | 187.5 | 163.4 | 156.7 | 119.9 | 91.7 | 46.3 |
| Net margin | 8.4% | 11.2% | 12.1% | 11.7% | 12.6% | 11.6% | 10.9% | 6.4% |
| |
| Basic EPS [+] | $1.07 | $1.28 | $1.58 | $1.38 | $1.34 | $1.05 | $0.81 | $0.42 |
| Growth | -16.5% | -18.8% | 14.8% | 2.8% | 28.3% | 28.5% | 96.0% | -43.1% |
| Diluted EPS [+] | $1.06 | $1.28 | $1.56 | $1.36 | $1.32 | $1.03 | $0.81 | $0.41 |
| Growth | -16.6% | -18.4% | 14.9% | 3.0% | 28.3% | 27.8% | 95.8% | -42.9% |
| |
| Dividends per share [+] | $0.60 | $0.58 | $0.43 | $190.00 | $105.00 | $525.00 | | |
| Growth | 3.4% | 34.9% | -99.8% | 81.0% | -80.0% | | | |
| |
| Shares outstanding (basic) [+] | 118.7 | 118.0 | 118.8 | 118.5 | 116.8 | 114.7 | 112.7 | 111.5 |
| Growth | 0.6% | -0.7% | 0.3% | 1.4% | 1.8% | 1.7% | 1.0% | 103.9% |
| Shares outstanding (diluted) [+] | 119.7 | 118.8 | 120.1 | 120.0 | 118.5 | 116.4 | 113.8 | 112.6 |
| Growth | 0.8% | -1.1% | 0.1% | 1.2% | 1.8% | 2.3% | 1.1% | 103.4% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|